Hostname: page-component-797576ffbb-pxgks Total loading time: 0 Render date: 2023-12-11T07:27:20.866Z Has data issue: false Feature Flags: { "corePageComponentGetUserInfoFromSharedSession": true, "coreDisableEcommerce": false, "useRatesEcommerce": true } hasContentIssue false
  • English
  • Français

HIV-1–Associated Cognitive-Motor Disorders: A Research-Based Approach to Diagnosis and Treatment

Published online by Cambridge University Press:  07 November 2014

Karl Goodkin ,
Frances. L. Wilkie ,
Teri T. Baldewicz ,
Mauricio Concha ,
Mary D. Tyll ,
Charles J. LoPiccolo  and
Paul Shapshak
Get access Rights & Permissions [Opens in a new window]

Abstract

The diagnosis of human immunodeficiency virus type 1 (HIV-1)–associated cognitive-motor disorder—either minor cognitive-motor disorder (MCMD) or HIV-1-associated dementia (HAD)—is fraught with potential pitfalls for the clinician. Before making such a diagnosis, clinicians should exclude other etiologies by using neuroimaging, lumbar puncture, and serum chemistries to screen for opportunistic and non-opportunistic infections of the brain and meninges. Clinicians should also consider psychoneurotoxicity (caused from the use of psychoactive substances and prescribed medications) and psychopathology, such as mood, anxiety, and other disorders. In addition, a thorough medical history and physical examination, including a complete neurologic and neuropsychiatric mental status examination, are necessary for an accurate diagnosis. There is also a need for standardized neuropsychological and functional status tests, since the diagnostic criteria for these disorders are partly based on these criteria. Treatment targets should include subclinical cognitive-motor impairment and neuroprotection, as well as MCMD and HAD. Currently, zidovudine remains the best proven treatment for these disorders, but other nucleoside reverse transcriptase inhibitors, as well as nonnucleoside reverse transcriptase inhibitors and protease inhibitors, show promise, and selected agents from these classes are being tested in clinical trials. Other areas that should be investigated are the modulation of inflammatory mediators (such as tumor necrosis factor α), neurotransmitter manipulation (especially of dopamine), and nutritional interventions.

Type
Grand Rounds
Information
CNS Spectrums , Volume 5 , Issue 8: Neuroscientific Approach to Emotions and Feelings: The Last Frontier of the New Millennium , August 2000 , pp. 49 - 60
Copyright
Copyright © Cambridge University Press 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Gabuzda, D, Olshevsky, V, Bertani, P, et al.Identification of membrane anchorage domains of the HIV-1 gp160 envelope glycoprotein precursor. J Acq Immun Defic Syndr. 1991;4:34–40.Google Scholar
2.Petito, CK, Roberts, B. Evidence of apoptotic cell death in HIV encephalitis. Am J Pathol. 1995;146:1121–1130.Google Scholar
3.Fujimura, RK, Goodkin, K, Petito, CK, et al.HIV-1 proviral DNA load across neuroanatomical regions of individuals with evidence for HIV-1 associated dementia. J AIDS Hum Retrovirol. 1997;16:146–152.Google Scholar
4.Montagnier, L. Lymphadenopathy-associated virus: from molecular biology to pathogenicity. Ann Int Med. 1985;103:689–693.Google Scholar
5.Shapshak, P, Fujimura, RK, Srivastava, , et al.Dementia and the Neurovirulence of HIV-1. CNS Spectrums. 2000;5(4):31–42.Google Scholar
6.Ho, DD, Pomerantz, RJ, Kaplan, JC. Pathogenesis of infection with human immunodeficiency virus. New Engl J Med. 1987;317:278–286.Google Scholar
7.Gallo, RC. Human tumor and immunodeficiency viruses. AIDS Res Hum Retrovir. 1987;3(suppl):187–196.Google Scholar
8.Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mort Wkly Rep. 1992;41(No.RR-17):1–19.Google Scholar
9.Vanhems, P, Dassa, C, Lambert, J, et al.Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection. J AIDS. 1999;21:99–106.Google Scholar
10.Perelson, AS, Neumann, AU, Markowitz, M, et al.HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582–1586.Google Scholar
11.American Academy of Neurology AIDS Task Force (Working Group). Nomenclature and research definition for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Neurology. 1991;41:778–785.Google Scholar
12.McNair, DM, Kahn, RJ. The cognitive difficulties scale. In: Thomas, Crook, Steven, Ferris, and Raymond, Bartus, eds. Assessment in Geriatric Psychopharmacobgy. New Canaan, CN: Mark Powley Associates; 1983:137–143.Google Scholar
13.Wu, AW, Rubin, HR, Mathews, WC, et al.A health status questionnaire using 30 items from the Medical Outcomes Study: preliminary validation in persons with early HIV infection. Med Care. 1991;29:786–798.Google Scholar
14.Wilkie, FL, Goodkin, K, Zuilen, MH, et al.Cognitive Effects of HIV-1 Infection. CNS Spectrum. 2000;5(5):33–51.Google Scholar
15.Goodkin, K, Wilkie, FL, Concha, M, et al.Subtle neuropsychological impairment and minor cognitive-motor disorder in HIV-1 Infection: neuroradiological, neurophysiological, neuroimmunological, and virological correlates. Neuroimaging Clin No Amer. 1997;7:561–579.Google Scholar
16.Shapshak, P, Segal, SM, Crandall, KA, et al.Independent evolution of HIV type 1 in different brain regions. AIDS Res Hum Retrovir. 1999;15(9):811–820.Google Scholar
17.Berger, JR, Kumar, M, Kumar, A, et al.Cerebrospinal fluid dopamine in HIV infection. AIDS. 1994;8:67–71.Google Scholar
18.Sardar, AM, Czudek, C, Reynolds, GP. Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS. Neuroreport. 1996;7:910–912.Google Scholar
19.Mirsattari, SM, Power, C, Nath, A. Parkinsonism with HIV infection. Movement Disorders. 1998;13:684–689.Google Scholar
20.Gisslen, M, Larsson, M, Norkrans, G, et al.Tryptophan concentrations increase in cerebrospinal fluid and blood after zidovudine treatment in patients with HIV type 1 infection. AIDS Res Hum Retroviruses. 1994;10:947–951.Google Scholar
21.Navia, BA, Khan, A, Pumarola-Sune, T, Price, RW. Choline acetyltransferase activity is reduced in the AIDS dementia complex. Ann Neurol. 1986;20:142.Google Scholar
22.Concha, M, Rabinstein, A. Central nervous system opportunistic infections in HIV-1 infection. CNS Spectrums. 2000;5(4):43–60.Google Scholar
23.Harrington, WJ, Miller, GA, Kemper, RR, et al.HTLV-I associated leukemia/lymphoma in South Florida. J of AIDS. 1991;4:284–289.Google Scholar
24.Chang, L, Miller, BL, McBride, D. et al.Brain lesions in patients with AIDS: H1 MR spectroscopy. Radiology. 1995;197:525–531.Google Scholar
25.Clifford, DB, Yiannoutsos, C, Glicksman, M, et al.HAART improves prognosis in HIV-1-associated progressive multifocal leukoencephalopathy. Neurology. 1999;52:623–625.Google Scholar
26.Berger, JR, Levy, RM, Flomenhoft, D, et al.Predictive factors for prolonged survival in AIDS-associated PML. J Neurovirol. 1998;4(3)(abstract):342.Google Scholar
27.Hall, CD, Dafni, U, Simpson, D, et al.Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med. 1998;338:1345–1351Google Scholar
28.Khouzam, HR, Donnelly, NJ, Ibrahim, NF. Psychiatric morbidity in HIV patients. Can J Psychiatry. 1998;43:51–56.Google Scholar
29.Maj, M. Organic mental disorders in HIV-1 infection. AIDS. 1990;4:831–840.Google Scholar
30.Atkinson, JH, Grant, I, Kennedy, CJ, et al.Prevalence of psychiatric disorders among men infected with human immunodeficiency virus. Archives of General Psychiatry. 1988;45:859–864.Google Scholar
31.Williams, JB, Rabkin, JG, Remien, RH, et al.Multidisciplinary baseline assessment of homosexual men with and without human immunodeficiency virus infection. II. Standardized clinical assessment of current and lifetime psychopathology. Arch Gen Psychiatry. 1991;48:124–130.Google Scholar
32.Perry, NM. Alcohol use in HIV patients: what we don't know may hurt us. Int J STD AIDS. 1999;10:561–571.Google Scholar
33.Perretta, P, Nisita, C, Zaccagnini, E, et al.Psychopathology in 90 consecutive human immunodeficiency virus-seropositive and acquired immune deficiency syndrome patients with mostly intravenous drug use history. Compr Psychiatry. 1996;37:267–272.Google Scholar
34.Goodkin, K. Psychiatric disorders in HIV-spectrum illness. Tex Med. 1988;84(9):55–61.Google Scholar
35.Lyketsos, CG, Hoover, DR, Guccione, M, et al.Changes in depressive symptoms as AIDS develops. The Multicenter AIDS Cohort Study. Am J Psychiatry. 1996;153:1430–1437.Google Scholar
36.Goodkin, K, Blaney, NT, Tuttle, RS, et al.Bereavement and HIV infection. Intl Rev Psychiatry. 1996;8:201–216.Google Scholar
37.Goodkin, K, Blaney, NT, Feaster, DJ, et al.A randomized controlled trial of a bereavement support group intervention in human immunodeficiency virus type 1-seropositive and seronegative homosexual men. Arch Gen Psychiatry. 1999;55:52–59.Google Scholar
38.Rush, AJ, Weissenburger, J, Vinson, DB, et al.Neuropsychological dysfunctions in unipolar nonpsychotic major depressions. J Affect Disord. 1983;5:281–287.Google Scholar
39.Channon, S, Green, PS. Executive function in depression: the role of performance strategies in aiding depressed and non-depressed participants. J Neurol Neurosurg Psychiatry. 1999;66:162–171.Google Scholar
40.Asthana, HS, Mandal, MK, Khurana, H, et al.Visuospatial and affect recognition deficit in depression. J Affect Disord. 1998;48:57–62.Google Scholar
41.Dolan, RJ, Bench, CJ, Brown, RG, et al.Neuropsychological dysfunction in depression: the relationship to regional cerebral blood flow. Psychol Med. 1994;24:849–857.Google Scholar
42.Nemeroff, CB, Krishnan, KR, Reed, D, et al.Adrenal gland enlargement in major depression. Arch Gen Psychiatry. 1992;49:384–387.Google Scholar
43.Sheline, YI, Wang, PW, Gado, MH, et al.Hippocampal atrophy in recurrent major depression. Proc Nat Acad Sci USA. 1996;93:3908–3913.Google Scholar
44.Wilkie, FL, Goodkin, K. Cognitive Function in HIV-1 infection. In: Goodkin, K, Visser, APh, eds. Psychoneuroimmunology: Stress, Mental Disorders and Health. Washington, DC: American Psychiatric Press; 2000:231–290.Google Scholar
45.Bell, JE, Donaldson, YK, Lowrie, S, et al.Influence of risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients. AIDS. 1996;10:493–499.Google Scholar
46.Goodkin, K, Shapshak, P, Metsch, L, et al.Cocaine abuse and HIV-1: Epidemiology and neuropathogenesis. Ann Neurol. 1999;45:816–821.Google Scholar
47.Fletcher, JM, Page, JB, Francis, DJ, et al.Cognitive correlates of long-term cannabis use in Costa Rican Men. Arch Gen Psychiatry. 1996;53:1051–1057.Google Scholar
48.Sidtis, JJ, Gatsonis, C, Price, RW, et al.Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled clinical trial. Ann Neurol. 1993;33:343–349.Google Scholar
49.Montforte, A, Musicco, M, Galli, M, et al.Italian mutlicentre study of didanosine compassionate use in advanced HIV infection. Eur J Microb Infect Dis. 1997;16:135–142.Google Scholar
50.McIntyre, K, Torres, R, Luck, D, et al.Pilot study of zidovudine (AZT) and zalcitabine (ddC) combination in HIV-associated dementia. Tenth International Conference on AIDS. Book of Abstracts, Yokohama, Japan, 8/8-8-12-94, #PB-0233, v.1, p. 201, 1994.Google Scholar
51.Thomas, SA, Segal, MB. The transport of the anti-HIV drug, 2N,3N-didehydro-3N-deoxythymidine (d4T), across the blood-brain and blood-cerebrospinal fluid barriers. Br J Pharmacol. 1998;125:49–54.Google Scholar
52.Brew, BJ, Brown, SJ, Catalan, J. et al. Safety and efficacy of abacavir (ABC, 1592) in AIDS dementia complex (study CNAB 3001). Abstracts of XIIth Int Conf on AIDS. Geneva, Switzerland: Int AIDS Society, Abstract #561/32192, p. 559, 1998.Google Scholar
53.Brew, BJ, Dunbar, N, Druett, JA, Freund, J, Ward, P. Pilot study of the efficacy of atevirdine in AIDS dementia complex. AIDS. 1996;10:1358–1360.Google Scholar
54.Stahle, L, Martin, C, Svensson, JO, et al.Indinavir in cerebrospinal fluid of HIV-1 infected patients. Lancet. 1997;350:1823.Google Scholar
55.Martin, C, Sonnerborg, A, Svensson, JO, et al.Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. AIDS. 1999;13:1227–1232.Google Scholar
56.Galgani, S, Narciso, P, Balestra, P, et al.Nimodipine + ZDV in patients with ADC. Tenth International Conference on AIDS. Book of Abstracts, Yokohama, Japan, 8/8-8-12-94, #PB-0248, v.1, p. 205, 1994.Google Scholar
57.Navia, BA, Dafni, U, Simpson, D, et al.A phase I/II trial of nimodipine for HIV-related complications. Neurology. 1998;51:221–228.Google Scholar
58.Heseltine, PNR, Goodkin, K, Atkinson, JH, et al.Randomized, double-blind placebo-controlled trial of Peptide T for HIV-associated cognitive impairment. Arch Neurol. 1998;55:41–51.Google Scholar
59.Rosen, MI, Bridge, TP, O'Malley, SS, et al.Peptide T treatment in HIV-positive intravenous drug users. Am J Addictions. 1992;1(4):332–338.Google Scholar
60.Simpson, DM, Dorfman, D, Olney, RK, et al.Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. Neurology. 1996;47:1254–1259Google Scholar
61.Albers, GW, Saenz, RE, Moses, JA. Tolerability of oral dextromethorphan in patients with a history of brain ischemia. Clin Neuropharm. 1992;15(6):509–514.Google Scholar
62.Polles, A, Griffith, JL. Dextromethorphan-induced mania. Psychosomatics. 1996;37(1):71–73.Google Scholar
63.Black, RS, Barclay, LL, Nolan, KA, et al.Pentoxifylline and cerebrovascular dementia. J Am Geriatrics Soc. 1992;40:237–244.Google Scholar
64.Dinarello, CA, Gelfand, JA, Wolff, SM. Anticytokine strategies in the treatment of systemic inflammatory response syndrome. JAMA. 1995;269(14):1829–1835.Google Scholar
65.Strassman, G, D'Alessandro, F, Fong, M, et al.Suramin blocks the binding of interleukin-1 to its receptor and neutralizes IL-1 biological activities. Int J Immunopharmacol. 1994;16(11):931–939.Google Scholar
66.Cheson, BD, Levine, AM, Mildvan, D, et al.Suramin therapy in AIDS and related disorders. JAMA. 1987;258:1347–1351.Google Scholar
67.Mapou, RL, Law, WA, Wagner, K, et al.Neuropsychological effects of interferon alfa-n3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals. J Neuropsychiatry Clin Neurosci. 1996;8:74–81.Google Scholar
68.Schiffito, G, Sacktor, N, Marder, K, et al.Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurology. 1999;53:391–396.Google Scholar
69.Fernandez, F, Adams, F, Levy, JK. Cognitive impairment due to AIDS-related complex and its response to psychostimulants. Psychosomatics. 1988;29(1):38–46.Google Scholar
70.Kieburtz, KD, Epstein, LG, Gelbard, HA, et al.Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Arch Neurol. 1991;48:1281–1284.Google Scholar
71.Dana Consortium. A randomized, doubleblind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Neurology. 1998;50:645–651.Google Scholar
72.Wilkie, FL, Goodkin, K, Eisdorfer, C, et al.Mild cognitive impairment and risk of mortality in HIV-1 infection. J Neuropsychiatry Clin Neurosci. 1998;10:125–132.Google Scholar
73.Singer, EJ, Wilkins, J, Syndulko, K, et al.Cerebrospinal fluid (CSF) biogenic amines increase and cortisol levels decrease after zidovudine (AZT) therapy in subjects with the AIDS dementia complex (ADC), in Neurological and Neuropsychological Complications of HIV Infection. Program and Abstracts. Monterey, CA, Kenness Canada, Inc, 1990, p 145Google Scholar
74.Baldewicz, TT, Brouwers, P, Goodkin, K, et al.Nutritional Contributions to the CNS Pathophysiology of HIV-1 Infection and Implications for Treatment. CNS Spectrums. 2000;5(4):61–72.Google Scholar
75.Campa, A, Shor-Posner, G, Indacochea, F, et al.Mortality risk in selenium-deficient HIV-positive children. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:508–513.Google Scholar
76.Semba, RD, Graham, NMH, Caiaffa, WT, et al.Increased mortality associated with vitamin A deficiency during human immunodeficiency virus type 1 infection. Arch Intern Med. 1993;153:2149–2154.Google Scholar
77.Graham, NM, Sorenson, D, Odaka, N, et al.Relationship of serum copper and zinc levels to HIV-1 seropositivity and progression to AIDS. J Acquir Immune Defic Syndr. 1991;4:976–980.Google Scholar